OPTUNEINFORMATION
"NVCR_Clinical_Evidence_Flipbook_June-2024.pdf Optune Overview - new version! Includes most important research articles on outcomes and mechanism of action!
(Added 8/6/24)
Optune Patient Tips and Tricks!
(Added 3/11/24)
Article about the new TSA Protocol For Optune Users in US Airports
And here is the TSA memo
(Added 4/14/2023)
Novocure's Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
(Added 11/29/2022)
Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields
A must read for everyone. It shows biomarkers which can predict success with Optune to an amazing degree - over 80% survival at 4 years with the right biomarker score!
The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
This study shows that it is ok to use Optune when you have a shunt!
Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
Reports amazing increases in survival by adding Keytruda to Optune.(Added 3/30/22)
Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
For elderly patients, 15% 5 year survival in Optune group compared to 0% in control group.(Added 10/26/2021)
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response (added 2/25/2022)
This shows that Optune may enhance the effect of checkpoint inhibitors!
Long term followup on original Optune clinical trial
an astounding 20% survival at 15 years (in a small trial). Added 11/23/2020
High compliance with Optune™ linked to greatest survival benefit for glioblastoma
29% 5 year survival in high compliance group compared to 4.5% in control group.(Added 1/26/19)
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
Read this if you are going to use Optune™ - it will help prevent the most comon problems.
No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers or Defibrillators
(Added 11/21/17)
Results from the trial for newly diagnoes GBM:
5 year survival rate more than doubles the standard of care! (added 9/24/17)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs. Temozolomide Alone for Glioblastoma
This may become the new standard of care for Glioblastoma multiforme. (added 12/15/15)
FDA Approves Optune for Newly Diagnosed Glioblastoma Patients.
Risk of death reduced by 37%!
Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients
Optune can now be used even if you have a non programmable shunt
New data on how Tumor Treating Fields Works
The name of the treatment has been changed from Novocure TTF100-A to Optune™ on 11/14/2014
|
Optune™ is a unique new form of treatment for brain tumors: it uses Tumor Treating Fields (TTF) to kill dividing cells. These fields are delivered by removable transducer arrays that are placed on the head. Click here for a news video about the Novocure NovoTTF-100A.Click on the links below for more information on Optune™.
|